Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide Study - PubMed
3 hours ago
- #Tenofovir
- #Hepatitis B
- #Renal Safety
- The study compares renal safety between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients from Korea.
- Using nationwide claims data (2017–2020) with propensity matching, it found incidence rates of renal replacement therapy (RRT) were 0.56 per 1,000 person-years for TAF and 0.96 for TDF, with a non-significant adjusted hazard ratio of 0.67.
- TAF and TDF showed comparable renal safety regarding RRT and chronic kidney disease progression.
- Risk factors like male sex, older age, hypertension, cirrhosis, and smoking were linked to higher RRT risk, emphasizing the need for monitoring in these groups.